UCB Revenue and Competitors
Estimated Revenue & Valuation
- UCB's estimated annual revenue is currently $3.1B per year.
- UCB's estimated revenue per employee is $201,000
Employee Data
- UCB has 15362 Employees.
- UCB grew their employee count by 4% last year.
UCB's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | CFO | Commercial Finance | Reveal Email/Phone |
3 | Executive Assistant to VP Head Group Finance | Reveal Email/Phone |
4 | CEO & Chairman the Executive Committee | Reveal Email/Phone |
5 | Executive Assistant to VP Head Talent Acquisition, Learning & Development | Reveal Email/Phone |
6 | Assistant to VP & Head Talent Acquisition & Development | Reveal Email/Phone |
7 | Head Global Engineering & Facilities, VP | Reveal Email/Phone |
8 | Head Global Clinical Development, VP | Reveal Email/Phone |
9 | Personal Assistant to VP, Non-Clinical Development | Reveal Email/Phone |
10 | Safety Officer | Reveal Email/Phone |
UCB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $24.5M | 122 | 8% | N/A | N/A |
#2 | $10.7M | 53 | -17% | N/A | N/A |
#3 | $9.2M | 46 | 2% | N/A | N/A |
#4 | $24.1M | 120 | 5% | N/A | N/A |
#5 | $7.2M | 36 | -20% | N/A | N/A |
#6 | $27.7M | 138 | -30% | N/A | N/A |
#7 | $39.8M | 198 | 37% | N/A | N/A |
#8 | $0.5M | 5 | 25% | $50M | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $10.3M | 51 | 11% | N/A | N/A |
What Is UCB?
UCB aspires to be the patient-centric global biopharmaceutical leader, transforming the lives of people living with serious diseases. The company employs more than 8 000 people dedicated to the research, development and commercialisation of innovative medicines and patient solutions. Operating in more than 40 countries, UCB generated revenues of € 3.2 billion in 2011.
keywords:N/A
N/A
Total Funding
15362
Number of Employees
$3.1B
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
UCB News
UCB's General Meeting of Shareholders 2022. For financial year 2021: Gross dividend of 1.30 per share (+ 2.36%), payable 3 May 2022; All...
Julia Amunts of PeakProfiling Working alongside the team of UCB will support us in validating our voice technology that can potentially act...
According to Zacks, UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for...
SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds fr ...
SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds fr ...